ERS Genomics Ltd. and Cellecta, Inc. announced a non-exclusive license agreement to provide Cellecta with worldwide access to ERS Genomics’ CRISPR/Cas9 genome editing intellectual property for use in informing research tools and services.
ERS Genomics holds rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentier, who along with Dr. Jennifer Doudna at the University of California, Berkeley, adapted the CRISPR system into a breakthrough gene editing technology.
Cellecta said it is the first commercial provider “of a lentiviral-based CRISPR library targeting all 19,000+ human protein-coding genes, and an industry leader in RNAi and CRISPR technologies for the discovery and characterization of novel therapeutic targets.”
It said its off-the-shelf and custom genetic libraries, constructs, and kits are widely used in commercial and academic laboratories researching disease progression and therapeutic interventions.
“As a leader in advancing high-throughput genetic screening and discovery applications for novel therapeutic targets and drugs, Cellecta is adding to the growing list of companies who are making the CRISPR/Cas9 technology broadly accessible to the scientific community,” said Eric Rhodes, CEO of ERS Genomics.
“We are thrilled to be partnering with Cellecta on these aligned interests.”
Cellecta CEO Dr. Paul Diehl said: “CRISPR/Cas9 technology is proving to be an increasingly valuable tool for target discovery and validation applications.
“Cellecta is pleased to offer a growing portfolio of products and services to aid researchers in obtaining a deeper understanding of gene function using this important technology.”
Financial details of the agreement were not disclosed.